Search Results

Aethlon Medical, Inc. announced that, on June, 13, 2024, the Human Research Ethics Committee of the Central Adelaide Local Health Network granted full ethics approval for Aethlon’s safety, feasibility and dose-finding clinical trial of the Hemopurifier® in cancer patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo® .

Aethlon Medical, Inc. today announced that it will issue financial results for its fiscal year ended March 31, 2024 , at 4:15 p.m. ET on Thursday, June 27, 2024.

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases, today reported financial results for its fiscal year ended March 31, 2024 and provided an update on recent developments.

Aethlon Medical, Inc. (Nasdaq: AEMD) today provided the following update on its planned phase 1 safety, feasibility and dose-finding clinical trials of its Hemopurifier® in patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.

Aethlon Medical, Inc. announced the pricing of a public offering of an aggregate of 8,100,000 shares of its common stock, Class A warrants to purchase up to 8,100,000 shares of common stock, and Class B warrants to purchase up to 8,100,000 shares of common stock, at a combined public offering price of $0.58 per share and accompanying warrants.

Aethlon Medical, Inc. announced positive results from an in vitro binding study of its Hemopurifier® in removing extracellular vesicles from plasma.